How is it different from heparin?

Bivalirudin inhibits thrombin directly and does not need antithrombin, can inhibit clot-bound thrombin, and in trials generally caused less bleeding than heparin plus a GP IIb/IIIa inhibitor.

What are the main risks?

Bleeding is the principal risk, and some primary-PCI studies showed more early stent thrombosis, which is reduced by continuing a post-procedure infusion and using potent antiplatelet therapy.

How is it administered?

Only intravenously by clinicians during catheterization procedures, as a bolus plus infusion with dose reduction in renal impairment; it is not used outside a supervised hospital setting.

FDA-approved medicineaka Angiomax, Hirulog

Bivalirudin — Complete Research Guide (2026)

Last updated 2026-07-31

TL;DR

A synthetic 20-amino-acid direct thrombin inhibitor (hirudin analog), FDA-approved as an anticoagulant during percutaneous coronary intervention.

What is Bivalirudin?

Bivalirudin (brand name Angiomax) is a synthetic 20-amino-acid peptide and direct thrombin inhibitor, engineered as an analog of hirudin (the natural anticoagulant of medicinal leeches).

It is FDA-approved as an intravenous anticoagulant for patients undergoing percutaneous coronary intervention (PCI), including those with or at risk of heparin-induced thrombocytopenia.

Evidence is strong and human, drawn from large randomized trials (REPLACE-2, HORIZONS-AMI, MATRIX, BRIGHT, EUROMAX).

How does Bivalirudin work?

Bivalirudin binds directly and reversibly to both the catalytic (active) site and the substrate-recognition exosite of thrombin, inhibiting thrombin-mediated conversion of fibrinogen to fibrin and platelet activation.

Unlike heparin, it does not require antithrombin and can inhibit clot-bound thrombin.

What does the research say about Bivalirudin?

During PCI, bivalirudin with provisional GP IIb/IIIa inhibition gave ischemic protection comparable to heparin plus planned GP IIb/IIIa inhibition while causing significantly less bleeding. ^[1]
In primary PCI for STEMI, bivalirudin reduced major bleeding and 30-day cardiac mortality versus heparin plus a GP IIb/IIIa inhibitor. ^[2]
In acute MI patients undergoing PCI, bivalirudin lowered net adverse clinical events, driven mainly by reduced bleeding, versus heparin-based regimens. ^[4]

Clinical research & studies

The references below are the primary sources cited throughout this guide. Each links directly to PubMed or the regulator. Where evidence is preclinical (animal or in-vitro), that is stated rather than implied.

[1] Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial — Lincoff AM et al., JAMA 2003. (Randomized controlled trial (REPLACE-2))
[2] Bivalirudin during primary PCI in acute myocardial infarction — Stone GW et al., New England Journal of Medicine 2008. (Randomized controlled trial (HORIZONS-AMI))
[3] Bivalirudin or Unfractionated Heparin in Acute Coronary Syndromes — Valgimigli M et al., New England Journal of Medicine 2015. (Randomized controlled trial (MATRIX))
[4] Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction: the BRIGHT randomized clinical trial — Han Y et al., JAMA 2015. (Randomized controlled trial (BRIGHT))
[5] Bivalirudin started during emergency transport for primary PCI — Steg PG et al., New England Journal of Medicine 2013. (Randomized controlled trial (EUROMAX))

Dosing context

This is not medical advice or a usage recommendation. Dosing figures are reported research context only, cited from the published literature.

In clinical practice bivalirudin is administered intravenously (bolus plus infusion) during catheterization procedures, with dose reduction for renal impairment and monitoring via activated clotting time.

This is regulatory and educational context only, not dosing guidance for any non-clinical use.

Side effects & safety profile

Bleeding remains the main safety concern, though across trials bivalirudin generally caused less major bleeding than heparin combined with a GP IIb/IIIa inhibitor.

A recognized trade-off is a higher rate of early acute stent thrombosis seen in some primary-PCI trials (HORIZONS-AMI, EUROMAX), which is mitigated by a post-PCI bivalirudin infusion and adequate P2Y12 inhibition.

It is cleared partly by the kidneys, so the dose is reduced in renal impairment, and it is an intravenous, hospital-only agent.

Stacking & combinations

It is used with aspirin and a P2Y12 inhibitor during PCI, and only selectively (provisionally) combined with a GP IIb/IIIa inhibitor because layering anticoagulants raises bleeding risk.

Finding Bivalirudin vendors

This is an independent, neutral directory — we sell nothing and route no purchases. Use it to read regulatory context and (where available) genuine, moderated vendor information for your country.

Choose your country

We never list placeholder vendors. Pick your country to see neutral regulatory context.

Browse the directory

User reviews

No reviews yet

Reviews appear here once submitted and moderated. An aggregate rating is shown only after at least 5 genuine reviews — we never fabricate ratings.

Frequently asked questions

Yes, it is a synthetic 20-amino-acid peptide designed as an analog of hirudin, functioning as a direct thrombin inhibitor and anticoagulant.

References

[1] Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial — Lincoff AM et al., JAMA 2003. PMID: 12588269. View sourceStudy: Randomized controlled trial (REPLACE-2)Bivalirudin with provisional GP IIb/IIIa blockade was non-inferior to heparin plus planned GP IIb/IIIa blockade for ischemic endpoints during PCI, with significantly less bleeding.
[2] Bivalirudin during primary PCI in acute myocardial infarction — Stone GW et al., New England Journal of Medicine 2008. PMID: 18499566. View sourceStudy: Randomized controlled trial (HORIZONS-AMI)In STEMI primary PCI, bivalirudin reduced major bleeding and 30-day cardiac and all-cause mortality versus heparin plus a GP IIb/IIIa inhibitor, but increased early acute stent thrombosis.
[3] Bivalirudin or Unfractionated Heparin in Acute Coronary Syndromes — Valgimigli M et al., New England Journal of Medicine 2015. PMID: 26324049. View sourceStudy: Randomized controlled trial (MATRIX)In ACS patients, bivalirudin did not significantly reduce major adverse cardiovascular events versus heparin but was associated with less bleeding and lower mortality.
[4] Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction: the BRIGHT randomized clinical trial — Han Y et al., JAMA 2015. PMID: 25775052. View sourceStudy: Randomized controlled trial (BRIGHT)In AMI patients undergoing PCI, bivalirudin (with prolonged post-procedure infusion) reduced net adverse clinical events versus heparin or heparin plus tirofiban, mainly through less bleeding, without excess stent thrombosis.
[5] Bivalirudin started during emergency transport for primary PCI — Steg PG et al., New England Journal of Medicine 2013. PMID: 24171490. View sourceStudy: Randomized controlled trial (EUROMAX)Bivalirudin begun during ambulance transport for primary PCI reduced major bleeding versus heparin/GP IIb/IIIa inhibitor regimens but increased acute stent thrombosis.

Related peptides

EptifibatideTherapeutic Peptides

This article is for educational and research purposes only. Peptides discussed here are not approved for human consumption by the FDA, EMA, or equivalent regulators outside of specific clinical contexts. Always consult a licensed medical professional before any therapeutic use.